Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Pharma firms testing weight loss drugs for kids amid Ozempic craze
05:12pm, Friday, 20'th Oct 2023
Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are
Drugmakers test weigh-loss shots for kids as young as 6
03:30pm, Friday, 20'th Oct 2023
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss the latest weight loss headlines.
Eli Lilly planning diabetes drug trial for children six years and older: report
01:01pm, Friday, 20'th Oct 2023
Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomberg report Friday citing a person familiar with t
DGRO: Can Dividends Generate Alpha?
11:40am, Friday, 20'th Oct 2023
DGRO: Can Dividends Generate Alpha?
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
10:00am, Friday, 20'th Oct 2023
INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a conference ca
Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg
06:35am, Friday, 20'th Oct 2023
Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.
Hundreds of online sellers are offering an Eli Lilly weight-loss drug that's years away from regulatory approval: WSJ
06:24am, Friday, 20'th Oct 2023
Hundreds of online sellers are offering Eli Lilly' & Co.'s LLY, -2.71% retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory approval, the Wall Street Journ
Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro
04:58pm, Thursday, 19'th Oct 2023
Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
04:11pm, Thursday, 19'th Oct 2023
This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.
Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
01:58pm, Thursday, 19'th Oct 2023
Eli Lilly has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday.
1 Market-Beating Stock to Buy Near Its 52-Week High
09:30am, Thursday, 19'th Oct 2023
Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
4 Ways to Grow $100,000 Into $1 Million for Retirement
09:13am, Thursday, 19'th Oct 2023
Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
The Next Trillion-Dollar Companies: 3 Stocks to Buy Now
06:51pm, Wednesday, 18'th Oct 2023
The hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech stocks to new highs while others reversed the
Eli Lilly is buying another European cancer firm Mablink Bioscience
10:01am, Wednesday, 18'th Oct 2023
Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-drug conjugates for cancer. It's the 2nd cancer compa
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
06:47pm, Tuesday, 17'th Oct 2023
Eli Lilly (LLY) reachead $608.31 at the closing of the latest trading day, reflecting a -1.35% change compared to its last close.
